Gertjan Rasschaert, Gastroenterologist and Digestive Oncologist at University Hospitals Leuven and researcher at KU Leuven, shared by Manish A. Shah, Director of GI Oncology at Weill Cornell Medicine, on LinkedIn:
“Congratulations to the Weill Cornell Medicine team on the publication of their pioneering work. Let’s continue our quest to unlock pMMR CRC for neoadjuvant immunotherapy.”
Quoting Manish Shah:
“Colorectal cancer is generally resistant to immunotherapy. However, we show in our neoadjuvant immunotherapy clinical trial that immunotherapy can be quite effective.
Using Botensilimab – Fc enhanced to deplete Tregs in the tumor microenvironment – with Balstilimab (PD-1 inhibitor), we demonstrate evidence of tumor remodeling associated with an anti tumor immune response! Check it out!”
Title: Neoadjuvant Botensilimab/Balstilimab for localized mismatch repair proficient and deficient colon cancer: Results of the NEST phase 2 clinical trial
Authors: Manish A. Shah, Erika Hissong, Mehraneh D. Jafari, Pashtoon Murtaza Kasi, Maider Astorkia, Sahrish Khan, Casey Owens, Zhengming Chen, Heather Yeo, Fabio Socciarelli, Sandipto Sarkar, Alana Nguyen, Despina Siolas, Allyson Ocean, Kelly Garrett, Lea Lowenfeld, Alessio Pigazzi, Preethi Guniganti, Sanjay Patel, Doron Betel, Manuel Hidalgo
Read The Full Article
You can also read:Phase 3 BATTMAN Trial Launches BOT/BAL in MSS or pMMR Metastatic Colorectal Cancer
